Global Health & Medicine 2024;6(4):277-281.

Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma

Sakai T, Ueda Y, Yanagisawa H, Arita K, Iwao H, Yamada K, Mizuta S, Kawabata H, Fukushima T, Tai K, Kishi S, Morinaga K , Murakami J, Takamatsu H , Terasaki Y, Yoshio N, Kondo Y, Okumura H, Matano S , Yamaguchi M, Tsutani H, Masaki Y

This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.

DOI: 10.35772/ghm.2024.01021

Full Text: